Conversion of the phytoestrogen coumestrol into a selective estrogen receptor modulator (SERM) by attachment of an amine-containing sidechain

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 22, 1996, Pages 2683-2686

  Grese, Timothy A ^a   Cole, Harlan W ^a   Magee, David E ^a   Phillips, D Lynn ^a   Shetler, Pam K ^a   Short, Lorri L ^a   Glasebrook, Andrew L ^a   Bryant, Henry U ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTILIPEMIC AGENT; CHOLESTEROL; COUMESTROL; COUMESTROL DERIVATIVE; EOSINOPHIL PEROXIDASE; ESTRADIOL; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; LIPID METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ORAL DRUG ADMINISTRATION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; UTERUS WEIGHT;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS;

EID: 0030593866     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(96)00502-1     Document Type: Article

References (24)

1. 1. (a) Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. Curr. Med. Chem. 1994, I, 61.
2. (b) Miquel, J.-F.; Gilbert, J. J. Steroid Biochem. 1988, 31, 525.
3. 2. (a) Miksicek, R. J. Mol. Pharmacol. 1993, 44, 37.
4. (b) Markiewicz, L.; Garey, J.; Adlercreutz, H.; Gurpide, E. J. Steroid Biochem. Molec. Biol. 1993, 45, 399.
5. (c) Molteni, A.; Brizio-Molteni, L.; Persky, V. J. Nutrition 1995, 125, 751S.
6. (d) Whitten, P. L.; Lewis, C.; Russell, E.; Naftolin, F. J. Nutrition 1995, 125, 771S.
7. (e) Medlock, K. L.; Branham, W. S.; Sheehan, D. M. Proc. Soc. Exper. Biol. Med. 1995, 208, 307; and references therein.
8. 3. (a) Dodge, J. A.; Glasebrook, A. L.; Magee, D. E.; Phillips, D. L.; Sato, M.; Short, L. L.; Bryant, H. U. J. Steroid Biochem. 1996, in press; and references therein.
9. (b) Knight, D. C.; Eden, J. A. Obstetrics Gynecol. 1996, 87, 897.
10. (c) Stone, R. Science 1994, 265, 308.
11. (d) Hileman, B. Chem. Eng. News 1994, 72, 19.
12. 4. (a) Salman, M. D.; Ray, S.; Agarwal, A. K.; Durani, S.; Setty, B. S.; Kamboj, V. P.; Anand, N. J. Med. Chem. 1983, 26, 592.
13. (b) Sharma, A. P.; Saeed, A.; Durani, S.; Kapil, R. S. J. Med. Chem. 1990, 33, 3222; and references therein.
14. (c) Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cole, H. W.; Kim, J. R.; Magee, D. E.; Rowley, E. R.; Sato, M. Bioorg. Med. Chem. Lett. 1996, 6, 903.
15. 5. For general reviews on SERMs see: (a) Grese, T. A.; Dodge, J. A. In Annual Reports in Medicinal Chemistry: Bristol, J. A., Ed.; Academic: New York, 1996; Vol. 31, in press.
16. (b) Kauffman, R. F.; Bryant, H. U. Drug News Perspec. 1995, 8, 531.
17. (c) Evans, G. L.; Turner, R. T. Bone 1995, 17, 181S.
18. 6. Grese, T. A.; Pennington, L. D. Tetrahedron Lett. 1995, 36, 8913.
19. 7. Glasebrook, A. L.; Phillips, D. L.; Sluka, J. P. J. Bone Miner. Res. 1993, 8 (Suppl 1), S268.
20. 8. Thompson, E. W.; Reich, R.; Shima, T. B.; Albini, A.; Graf, J.; Martin, G. R.; Dickson, R. B.; Lippman, M. E. Cancer Res. 1988, 48, 6764.
21. 9. A description of this assay has been published previously; Grese, T. A.; Cho, S.; Bryant, H. U.; Cole, H. W.; Glasebrook, A. L.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L. Bioorg. Med. Chem. Lett. 1996, 6, 201.
22. 10. Alternative mechanisms which do not involve interaction with the estrogen receptor have been proposed to explain the cholesterol lowering activities of tamoxifen and other antiestrogens, and cannot be ruled out by the data from the present study: Gylling, H.; Mäntylä, E.; Miettinen, T. A. Atherosclerosis 1992, 96, 245.
23. 11. Bryant, H. U.; Wilson, P. K.; Adrian, M. D.; Cole, H. W.; Short, L. L.; Dodge, J. A.; Grese, T. A.; Sluka, J. P.; Glasebrook, A. L. J. Soc. Gynecol. Invest. 1996, 3(Suppl), 152A.
24. 13C NMR, IR, and MS or elemental analysis.